Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: biodoc who wrote (5914)	10/24/1998 8:45:00 AM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

Oh, I see! So there is equivalence in efficacy and equivalence in safety. Because the heparin doses were high in relation to hirulog, and the claim was for greater safety, that greater safety wasn't proven. But greater efficacy wasn't the issue. With Vasomax, it is less effective than Viagra, but greater effectiveness need not be proven, since there won't need to be a comparison to Viagra, because a different target population will be claimed? If the target population were the same, would greater efficacy be an issue? Or is that never an issue? Drugs do have to have some efficacy, yes? --Linda